Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05506462
Other study ID # 21EERPZ01
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date January 2023
Est. completion date February 2024

Study information

Verified date August 2022
Source Ehave Inc.
Contact Jeffrey D Kamlet, MD
Phone 305 604 9595
Email jeffrey@tristarwell.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

There are many common pharmacological treatments for major depression disorder (MDD), however the efficacy of these drugs often fails in severe cases. Intravenous (IV) administered ketamine may offer the potential for remission of the symptoms in patients with MDD; however it has not yet been approved by FDA for this purpose. This study will make use of an electroencephalography (EEG) machine to measure the brain's activity and response while the IV ketamine is being delivered. The objective of this study is to characterize the change in EEG response of patients with MDD, during and 4 weeks after a course of IV ketamine infusions.


Description:

This study will enroll 35 patients with major depressive disorder. Candidates for participation in the study will typically be either referred to the clinic through their healthcare provider or will have sought out participation on their own accord based on advertising. Subjects will be screened for eligibility and suitable patients will be invited to attend a screening visit in the clinic and complete informed consent. Upon determining eligibility, subjects will have their first treatment session booked within 42 days of screening (Baseline, visit 0). Three subsequent weekly (±3 days) ketamine therapy treatment sessions will occur on days 7, 14 and 21, for a total of four ketamine infusions over four weeks. All patients will return for a follow-up visit at 4-weeks post final treatment visit, day 49.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 35
Est. completion date February 2024
Est. primary completion date January 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Individuals between 18 and 70 years of age, inclusive 2. Adult patients with a documented primary Axis I clinical diagnosis meeting criteria from the DSM-V for a major depressive disorder 3. Score of <15 on the DES 4. Moderate to severe symptoms objectively documented using MADRS total score of = 20 5. Ability to maintain scheduled appointments for screenings, 4 treatment visits and follow-up EEG visit. 6. History of major depressive disorder. 7. Females of child-bearing potential who are sexually active must agree to use two forms of contraception. A pregnancy test will be performed before the first treatment. 8. Must have stable residence address, internet and mobile phone. 9. Must speak fluent English. Exclusion Criteria: 1. Known allergy to ketamine or any other drug used in the study. 2. Use of ketamine in a therapeutic model within the preceding 12 months of the study. 3. Current or any history of schizoaffective disorder(s). 4. Score of = 15 on DES 5. History of illicit active substance abuse or dependence including ketamine as determined on by the SCID-5-CT and/or drug urine screening during study visits. 6. Pregnancy, breastfeeding or desire to become pregnant during the course of the study. 7. Serious, unstable illnesses including, but not limited to; hepatic, gastro-intestinal, respiratory, cardiovascular (including ischemic heart disease and coronary heart disease). History of ischemic stroke, atrial fibrillation, severe endocrinological, neurological, immunological or hematological disease. 8. Any history of cerebral vascular events including stroke, bleeding into the brain and subdural hematomas. 9. Any implantable metallic device(s) or implant(s) above the level of shoulders. 10. Any non-removable metallic piercings. 11. Patients with cochlear implants and non-removable hearing aids. 12. Current use of: Dilantin, Depakote, Phenobarbital, Gabapentin, Pregabalin and Benzodiazepines. Certain candidates with long use of Benzodiazepines may qualify at PI's discretion. 13. Severe labile hypertension. 14. Significant uncontrolled hypertension (i.e., SBP > 150 mmHG, DBP > 100 mmHG) 15. Uncontrolled diabetes mellitus. 16. Patients on renal dialysis. 17. Inability to achieve consistent IV access.

Study Design


Intervention

Drug:
Ketamine Hydrochloride
Patients with a diagnosis of Major Depressive Disorder (MDD) will be enrolled to receive four 50-60 minute infusions of 60mg ketamine hydrochloride

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Ehave Inc. Tristar Wellness

Outcome

Type Measure Description Time frame Safety issue
Primary Characterizing the changes in EEG reading frequencies from pre- IV ketamine infusion treatment (baseline). Alpha, Beta, Delta, Theta and Gamma frequencies will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution 30-minute pre-treatment baseline and throughout infusion (approximately 50-60 minutes)
Primary Characterizing the changes in EEG reading waveforms from pre- IV ketamine infusion treatment (baseline). Alpha, Beta, Delta, Theta and Gamma waveforms will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution 30-minute pre-treatment baseline and throughout infusion (approximately 50-60 minutes)
Primary Characterizing the changes in EEG reading amplitudes from pre- IV ketamine infusion treatment (baseline). Alpha, Beta, Delta, Theta and Gamma amplitude will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution 30-minute pre-treatment baseline and throughout infusion (approximately 50-60 minutes)
Primary Characterizing the changes in EEG reading patterns from pre- IV ketamine infusion treatment (baseline). Alpha, Beta, Delta, Theta and Gamma reading patterns will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution 30-minute pre-treatment baseline and throughout infusion (approximately 50-60 minutes)
Primary Characterizing the changes in EEG reading frequencies from pre- IV ketamine infusion treatment (baseline) and 4 weeks post-treatment course Alpha, Beta, Delta, Theta and Gamma frequencies will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution Pre-treatment baseline, 4 weeks post-treatment course
Primary Characterizing the changes in EEG reading waveforms from pre- IV ketamine infusion treatment (baseline) and 4 weeks post-treatment course Alpha, Beta, Delta, Theta and Gamma waveforms will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution Pre-treatment baseline, 4 weeks post-treatment course
Primary Characterizing the changes in EEG reading amplitudes from pre- IV ketamine infusion treatment (baseline) and 4 weeks post-treatment course Alpha, Beta, Delta, Theta and Gamma amplitude will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution Pre-treatment baseline, 4 weeks post-treatment course
Primary Characterizing the changes in EEG reading patterns from pre- IV ketamine infusion treatment (baseline) and 4 weeks post-treatment course Alpha, Beta, Delta, Theta and Gamma amplitude will be examined with portable NeuroEEG™, a 19 channels and 22 electrodes cap based on 10-20 distribution Pre-treatment baseline, 4 weeks post-treatment course
Secondary Incidence of medically significant changes in blood pressure during ketamine infusion Pre-treatment baseline; treatment initiation, 0 minutes; 20 minutes, 40 minutes; 60 minutes post-infusion
Secondary Incidence of medically significant changes in Oxygen Saturation (SpO2) during ketamine infusion Pre-treatment baseline; treatment initiation, 0 minutes; 20 minutes, 40 minutes; 60 minutes post-infusion
Secondary Incidence of medically significant changes in heart rate during ketamine infusion Pre-treatment baseline; treatment initiation, 0 minutes; 20 minutes, 40 minutes; 60 minutes post-infusion
Secondary Incidence of medically significant changes in respiratory rate during ketamine infusion Pre-treatment baseline; treatment initiation, 0 minutes; 20 minutes, 40 minutes; 60 minutes post-infusion
Secondary Changes from baseline in the Dissociative Experiences Scale (DES) Total Score The Dissociative Experiences Scale (DES) is a 28-item scale assessing the subject's experiences in his/her daily life. The subject determines to what degree he/she has been facing the situation by selecting a percentage from 0% (never) to 100% (always), with 10% increments in between. Higher scores mean higher severity Baseline (Day 0), follow-up visit (Day 42)
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4